MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:31Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Angiotensin receptor blockers]]
			[[Category:Antihypertensives]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #85

2026-05-23T03:42:09Z

parser-claude batch MedTemplate pre-fill, Top 300 #85

New page

{{MedTemplate
| generic = Valsartan
| brand = Diovan; Entresto (in fixed-dose combination with sacubitril)
| structure =
| classes = [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]], [[:Category:Antihypertensives|Antihypertensive]]
| uses = <vote slug="hypertension-use">Hypertension</vote>, <vote slug="hfref-use">Heart failure with reduced ejection fraction</vote>, <vote slug="post-mi-use">Post-myocardial infarction</vote>
| starting_dose = 80-160 mg PO once daily (40 mg BID in HFrEF, titrating up to 160 mg BID)
| preparations = 40, 80, 160, 320 mg tablets; oral suspension
| fda_max = 320 mg/d (hypertension); 320 mg/d (HF)
| pill_id =
| routes = Oral
| onset = BP effect 2 hours; max at 4-6 weeks
| duration = 24 hours
| halflife = ~6 hours<ref name="diovan-label">FDA Prescribing Information, Diovan (valsartan), Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021283s039lbl.pdf</ref>
| bioavailability = ~25% (oral; food reduces absorption ~40%)<ref name="diovan-label" />
| pregnancy = '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection<ref name="diovan-label" />
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="valsartan-mech-claim">Valsartan is a selective AT1 angiotensin-II receptor antagonist; blocking AT1 produces vasodilation, decreased aldosterone, and reduced sodium retention without the bradykinin accumulation that drives ACE-inhibitor cough.</vote> Largely hepatically cleared (~80% biliary); no active metabolite. Sacubitril-valsartan (Entresto) combines an ARB with neprilysin inhibition for HFrEF and was a notable advance over the ARB-alone trial (PARADIGM-HF, 2014)<ref name="diovan-label" />.
}}

== References ==
<references />

Valsartan - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #85